SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Short Candidates
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (726)12/17/2004 10:20:41 AM
From: rkrw  Read Replies (3) of 897
 
<<OSIP's huge gap up on Iressa's failure to demonstrate survival benefit.>>>

I'm long osip and will cont to hold. Dominating rather than sharing the space is huge.

<<<<NBIX up as if the great label for Lunesta meant the FDA was going to be nice to them, too, and they've got Pfizer behind them, as well as 12 month studies, too, blah blah. Nothing has changed for NBIX, it was SEPR that had some uncertainty in it.>>>

I'd take 30% royalties, pfe marketing over owning it all and sepr marketing. Of course I own shares in both :-)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News